H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $6 from $10 and keeps a Buy rating on the shares. The firm cites the recent and anticipated equity dilution for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
- BTAI Upcoming Earnings Report: What to Expect?
- BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia
- BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity
- BioXcel completes updated market opportunity assessment for Igalmi